Moderna Inc. announced over the weekend that it dosed its first participants in each age cohort with its COVID-19 vaccine in the company’s Phase 2 study.
In a release, the biotechnology company explained that the study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
